CA-125 — obiecujący biomarker w niewydolności serca. Podsumowanie bieżącego stanu wiedzy
Streszczenie
Wciąż trwają poszukiwania odpowiednich biomarkerów do monitorowania i leczenia pacjentów z niewydolnością serca (HF). Nowy biomarker — antygen węglowodanowy 125 (CA-125), powszechnie używany do tej pory w onkologii, okazał się przydatny w ocenie zastoju oraz procesów zapalnych w niewydolności serca. Jego podwyższone wartości są ściśle związane z upośledzoną funkcją prawej komory. Co więcej, podwyższone stężenie CA-125 jest związane z ponownymi hospitalizacjami z powodu HF oraz wyższym ryzykiem zgonu. W związku z tym, pojawiła się potrzeba stworzenia potencjalnej strategii leczenia, co zostało wykonane w badaniu CHANCE-HF. Pomimo zalet tego biomarkera, takich jak powszechny dostęp lub znacząco niski koszt oznaczenia, konieczne jest przeprowadzenie wieloośrodkowych i międzynarodowych badań, aby wprowadzić odpowiednie wytyczne.
Słowa kluczowe: niewydolność sercaostra niewydolność sercaechokardiografiabiomarkerypraktyka kliniczna
Referencje
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Tymińska A, Kapłon-Cieślicka A, Filipiak KJ. Niewydolność serca — nowe biomarkery na horyzoncie? Choroby Serca i Naczyń. 2018; 15(4): 232–244.
- Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020; 17(10): 641–655.
- Woźniak-Wiśniewska A, Błażejewski J, Bujak R, et al. The value of cancer antigen 125 (Ca 125) and copeptin as markers in patients with advanced heart failure. Folia Cardiologica. 2017; 12(6): 537–542.
- Marcus C, Maxwell G, Darcy K, et al. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. Journal of Cancer. 2014; 5(1): 25–30.
- Kumric M, Kurir TT, Bozic J, et al. Carbohydrate antigen 125: a biomarker at the crossroads of congestion and inflammation in heart failure. Card Fail Rev. 2021; 7: e19.
- Hung CL, Hung TC, Lai YH, et al. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. Biomark Res. 2013; 1(1): 25.
- Vizzardi E, D'Aloia A, Curnis A, et al. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev. 2013; 21(1): 23–26.
- Girerd N, Seronde MF, Coiro S, et al. INI-CRCT, Great Network, and the EF-HF Group. Integrative assessment of congestion in Heart failure throughout the patient journey. JACC Heart Fail. 2018; 6(4): 273–285.
- Núñez J, Miñana G, Núñez E, et al. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail Rev. 2014; 19(5): 575–584.
- Huang F, Chen J, Liu Y, et al. New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses. 2012; 79(3): 381–383.
- Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, et al. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol. 1994; 47(3): 263–265.
- Bulska-Będkowska W, Chełmecka E, Owczarek AJ, et al. CA125 as a marker of heart failure in the older women: population-based analysis. J Clin Med. 2019; 8(5): 607.
- Colombo PC, Onat D, Harxhi A, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014; 35(7): 448–454.
- Turgut O, Tandogan I, Yilmaz MB, et al. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol. 2010; 145(1): 71.
- Soler M, Miñana G, Santas E, et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int J Cardiol. 2020; 308: 54–59.
- Santas E, Miñana G, Palau P, et al. Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure. Circ J. 2015; 79(7): 1526–1533.
- Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005; 7(2): 199–203.
- D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003; 41(10): 1805–1811.
- Zhang Yi, Jin Qi, Zhao Z, et al. Carbohydrate antigen 125 is a biomarker of the severity and prognosis of pulmonary hypertension. Front Cardiovasc Med. 2021; 8: 699904.
- Núñez J, de la Espriella R, Miñana G, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur J Heart Fail. 2021; 23(9): 1445–1457.
- Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, et al. Novel biomarkers of heart failure. Adv Clin Chem. 2017; 79: 93–152.
- Llàcer P, Gallardo MÁ, Palau P, et al. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. Med Clin (Barc). 2021; 156(12): 589–594.
- Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020; 116(1): 91–100.
- Yafasova A, Butt JH, Rørth R. Troponin: an important prognostic biomarker in patients with heart failure and reduced ejection fraction? Eur J Heart Fail. 2021; 23(9): 1539–1540.
- Melchio R, Rinaldi G, Testa E, et al. Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study. Intern Emerg Med. 2019; 14(2): 239–247.
- Piek A, Du W, de Boer RA, et al. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. 2018; 55(4): 246–263.
- Ponikowska B, Iwanek G, Zdanowicz A, et al. Biomarkers of myocardial injury and remodeling in heart failure. J Pers Med. 2022; 12(5): 799.
- Lourenço P, Cunha FM, Elias C, et al. CA-125 variation in acute heart failure: a single-centre analysis. ESC Heart Fail. 2022; 9(2): 1018–1026.
- Wang XY, Zhang F, Zhang C, et al. The biomarkers for acute myocardial infarction and heart failure. Biomed Res Int. 2020; 2020: 2018035.
- Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction. Vasc Health Risk Manag. 2019; 15: 221–227.
- Núñez J, Llàcer P, Bertomeu-González V, et al. Carbohydrate antigen 125-guided therapy in acute heart failure. JACC Heart Fail. 2016; 4(11): 833–843.
- Núñez J, Bayés-Genís A, Revuelta-López E, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail. 2020; 8(5): 386–397.
- Sawościan M, Lelonek M. Terapia inhibitorami kontransportera sodowo-glukozowego 2 – nie tylko dla diabetologów. Folia Cardiologica. 2021; 16(6): 389–393.
- de la Espriella-Juan R, Miñana G, Santas E, et al. Effects of empagliflozin on CA 125 trajectory in patients with chronic congestive heart failure. Int J Cardiol. 2021; 339: 102–105.
- Zhuang J, Faggiano P, Li Qi, et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies. J Cardiovasc Med (Hagerstown). 2014; 15(12): 864–872.
- Li KaH, Gong M, Li G, et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia. 2018; 10(2): e011044.
- Lorenzo M, Palau P, Llàcer P, et al. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. Eur J Intern Med. 2021; 92: 94–99.